Home / Biosimilars / General / Biosimilars of epoetin alfa

Biosimilars of epoetin alfa Posted 13/06/2014

Last update: 13 October 2017

Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anaemia, commonly associated with chronic renal failure and cancer chemotherapy.

The originator product, Amgen/Johnson & Johnson’s Epogen/Eprex/Procrit (epoetin alfa), was approved by the US Food and Drug Administration (FDA) in June 1989/February 1999 and by the European Medicines Agency (EMA) in June 1989 [1]. Epogen/Eprex had worldwide sales of US$3 billion in 2015, making up US$1.9 billion in sales for Amgen and US$1.07 billion for Johnson & Johnson.

The patents on Epogen/Eprex already expired in both the US and in Europe in 2013 [1], however, Amgen still has a patent protecting the cells that make certain levels of erythropoietin lasting until 26 May 2015. Some of the epoetin alfa biosimilars and non-originator biologicals* approved or in development are presented in Table 1.

Table 1: Biosimilars and non-originator biologicals* of epoetin alfa approved or in development

Company name, Country

Product name

Stage of development

Apotex (Apobiologix), Canada

Apo-EPO

Phase III trial in anaemia re-started

Biocon, India*

Erypro Safe

Prefilled syringes marketed in India following 2008 launch [2]

CCM Duopharma Biotech/PanGen Biotech, Malaysia/South Korea

PDA10

Phase III trial completed in February 2017

Claris Lifesciences, India*

Epotin

‘Similar biologic’ marketed in India [2]

Emcure, India*

Epofer

‘Similar biologic’ marketed in India [2]

Hexal, Australia

Epoetin alfa Hexal

Approved in EU in August 2007 for anaemia, cancer and chronic kidney failure [3]

Hospira (Pfizer), USA

Retacrit (epoetin zeta)

Approved in EU in December 2007 [3]. Recommended for approval in the US in May 2017 [4], rejected in June 2017 [5]

Intas Pharmaceuticals, India*

Epofit/Erykine

‘Similar biologic’ marketed in India, following 2005 launch [2]

Medice Arzneimittel Pütter, Germany

Abseamed

Approved in EU in August 2007 for anaemia, cancer and chronic kidney failure [3]

Ranbaxy, India*

Ceriton

‘Similar biologic’ marketed in India [2]

Reliance Life Sciences, India*

Relipoietin

‘Similar biologic’ marketed in India, following 2008 launch [2]

Sandoz, Switzerland

Binocrit

Marketed in the European Union in August 2007 for anaemia and chronic kidney failure [3]. Approved for SC route in April 2016 [6]

Sandoz, Switzerland

HX575

Phase III trial, comparing safety and efficacy of biosimilar with Epogen/Procrit in anaemia associated with chronic kidney disease started in the US in 2012 [7]. Expected completion in 2014.

Wockhardt, India*

Wepox

‘Similar biologic’ marketed in India, following 2001 launch [2]

EU: European Union.

*See editor’s comment

There are already three biosimilars approved for the European market and, with Sandoz already carrying out a phase III trial for its biosimilar in the US [7], it should not be too long before biosimilar epoetin alfa products hit the US market.

Both Hospira’s Retacrit and Stada’s Silapo (epoetin zeta) biosimilars have been approved by EMA for the same indications as Aranesp (darbepoetin alfa), i.e. anaemia, cancer and chronic kidney failure, as well as for autologous blood transfusion. Hospira has, however, submitted its application to FDA for Retacrit in the US as a biosimilar to Amgen’s Epogen (epoetin alfa) [6].

Editor’s comment
It should be noted that ‘similar biologics’ approved in India might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related article
Biosimilars of darbepoetin alfa

References
1. Derbyshire M. Patent expiry dates for biologicals: 2016 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(1):27-30. doi:10.5639/gabij.2017.0601.006
2. GaBI Online - Generics and Biosimilars Initiative. ‘Similar biologics’ approved and marketed in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 13]. Available from: www.gabionline.net/Biosimilars/General/Similar-biologics-approved-and-marketed-in-India
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 13]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
4. GaBI Online - Generics and Biosimilars Initiative. FDA advisors recommend approval of Pfizer’s epoetin alfa biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Jun 23]. Available from: www.gabionline.net/Biosimilars/News/FDA-advisors-recommend-approval-of-Pfizer-s-epoetin-alfa-biosimilar
5. GaBI Online - Generics and Biosimilars Initiative. FDA rejects Pfizer’s epoetin alfa biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 13]. Available from: www.gabionline.net/Biosimilars/News/FDA-rejects-Pfizer-s-epoetin-alfa-biosimilar
6. GaBI Online - Generics and Biosimilars Initiative. New administration route for epoetin alfa biosimilar Binocrit [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Jun 23]. Available from: www.gabionline.net/Biosimilars/News/New-administration-route-for-epoetin-alfa-biosimilar-Binocrit
7. GaBI Online - Generics and Biosimilars Initiative. Sandoz starts phase III US trial for biosimilar epoetin alfa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 13]. Available from: www.gabionline.net/Biosimilars/Research/Sandoz-starts-phase-III-US-trial-for-biosimilar-epoetin-alfa

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Amgen, EU Clinical Trials Register, Johnson & Johnson

Comments (0)